No increased chromosomal damage in l-DOPA-treated patients with Parkinson’s disease: a pilot study

@article{Oli2010NoIC,
  title={No increased chromosomal damage in l-DOPA-treated patients with Parkinson’s disease: a pilot study},
  author={Rajaraman Gnana Oli and Gholamreza Fazeli and Wilfried Kuhn and Susanne Walitza and Manfred Gerlach and Helga Stopper},
  journal={Journal of Neural Transmission},
  year={2010},
  volume={117},
  pages={737-746}
}
Parkinson’s disease (PD) is a neurodegenerative movement disorder affecting about 2% of the human population in old age. l-3,4-Dihydroxyphenylalanine (l-DOPA) in combination with a peripheral aromatic amino acid decarboxylase inhibition has been the most frequently prescribed drug for alleviating symptoms of PD, but a potential contribution of l-DOPA therapy to further neurodegeneration via oxidative stress is still debated. We report that the specific oxidative stress biomarker 8-oxo-7,8… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 15 CITATIONS

A multi-biomarker analysis of the antioxidant efficacy of Parkinson's disease therapy.

  • Toxicology in vitro : an international journal published in association with BIBRA
  • 2018
VIEW 3 EXCERPTS
CITES BACKGROUND & RESULTS

References

Publications referenced by this paper.
SHOWING 1-10 OF 50 REFERENCES

Spearman Rank Correlation (v1.0.0) in Free Statistics Software (v1.1.23-r6), Office for Research Development and Education

P Wessa
  • 2009
VIEW 1 EXCERPT
HIGHLY INFLUENTIAL

Genotoxicity of the neurotransmitter dopamine in vitro

H Stopper
  • Toxicol In Vitro
  • 2009

The stability of the oxidative stress marker, urinary 8-hydroxy-20- deoxyguanosine (8-OHdG), when stored at room temperature

Y Matsumoto, Y Ogawa
  • J Occup Health
  • 2008